A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine.
Animals
Antibodies, Viral
/ immunology
COVID-19
/ epidemiology
COVID-19 Vaccines
/ administration & dosage
Humans
Measles Vaccine
/ genetics
Measles virus
/ genetics
Mice
Pandemics
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ administration & dosage
T-Lymphocytes
/ immunology
Th1 Cells
/ immunology
COVID-19
SARS-CoV-2
Th1 immune bias
effective immunity
measles vaccine platform
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
22 12 2020
22 12 2020
Historique:
pubmed:
2
12
2020
medline:
20
1
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8
Identifiants
pubmed: 33257540
pii: 2014468117
doi: 10.1073/pnas.2014468117
pmc: PMC7768780
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Measles Vaccine
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32657-32666Informations de copyright
Copyright © 2020 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Lancet Infect Dis. 2015 May;15(5):519-27
pubmed: 25739878
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Vaccine. 2013 Aug 12;31(36):3718-25
pubmed: 23742993
F1000Res. 2018 Feb 28;7:237
pubmed: 29560260
J Virol. 2015 Nov;89(22):11654-67
pubmed: 26355094
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Curr Cancer Drug Targets. 2018;18(2):177-187
pubmed: 28228086
Leukemia. 2017 Dec;31(12):2791-2798
pubmed: 28439108
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Virology. 2014 Mar;452-453:32-41
pubmed: 24606680
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Virus Genes. 2017 Oct;53(5):733-740
pubmed: 28710608
Virology. 2018 Nov;524:151-159
pubmed: 30199752
J Virol. 1998 Sep;72(9):7420-7
pubmed: 9696838
Cell. 2020 Jul 9;182(1):50-58.e8
pubmed: 32516571
PLoS One. 2013;8(3):e58414
pubmed: 23516477
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Lancet. 2019 Dec 22;392(10165):2718-2727
pubmed: 30409443
Curr Top Microbiol Immunol. 2009;330:151-71
pubmed: 19203109
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Virology. 2018 Jun 11;521:99-107
pubmed: 29902727
Nat Rev Immunol. 2009 Apr;9(4):287-93
pubmed: 19247370
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
J Virol. 2004 Jan;78(1):146-57
pubmed: 14671096
Virus Res. 2014 Feb 13;180:43-8
pubmed: 24368277
Vaccine. 2019 Aug 23;37(36):5323-5331
pubmed: 31345639
Hum Vaccin Immunother. 2015;11(2):477-88
pubmed: 25692535
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Vaccine. 2008 Apr 16;26(17):2164-74
pubmed: 18346823
EMBO Rep. 2018 Feb;19(2):206-224
pubmed: 29282215
Immunity. 2001 Apr;14(4):461-70
pubmed: 11336691
Mayo Clin Proc. 2014 Jul;89(7):926-33
pubmed: 24835528